Please assess the completion status of the following clinical trial:

Trial Title: Dysport in Vulvodynia Phase II Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Premenopausal~* Have vulvodynia for at least 6 months and for no more than 15 years~* Have provoked pain at the vestibule on a Q tip test~Exclusion Criteria:~* Deep pain during intercourse~* Have genitourinary or gastrointestinal conditions which may interfere with the study~* Previous surgery that according to investigator's judgement may impact on study outcome (including but not limited to hysterectomy, vestibulectomy, urologic surgery, perianal surgery) or genital trauma or mutilation/cutting

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dysport - Dose Escalation stage 1 (Type: EXPERIMENTAL): Intramuscular injection of Dysport on day 1 of each cycle.
- Placebo - Dose Escalation stage 1 and Dose Expansion stage 2 (Type: PLACEBO_COMPARATOR): Intramuscular injection on day 1 of cycle 1.
- Dysport - Dose Expansion stage 2 (Type: ACTIVE_COMPARATOR): Depending upon the results from Stage 1 one or two doses of Dysport will be selected. Intramuscular injection of Dysport on day 1 of each cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).